1356409-09-0

Basic information

• Product Name: C₁₄H₁₆O₂
• Synonyms: C₁₄H₁₆O₂
• CAS NO: 1356409-09-0
• Molecular Weight: 216.28
• Mol File: 1356409-09-0.mol

Chemical Properties

• CAS DataBase Reference: C₁₄H₁₆O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₄H₁₆O₂(1356409-09-0)
• EPA Substance Registry System: C₁₄H₁₆O₂(1356409-09-0)

Safety Data

• Hazardous Substances Data: 1356409-09-0(Hazardous Substances Data)

Upstream product

• 79496-61-0 hex-5-ynyl methanesulphonate 
• 928-90-5 5-hexyl-1-ol 
• 101-41-7 benzeneacetic acid methyl ester 
• 2468-56-6 1-iodo-5-hexyne 

Downstream Products

• 1356409-08-9 C₁₈H₁₉NO₄ 
• 1356409-46-5 C₄₄H₆₆N₁₂O₈ 
• 1356409-87-4 C₄₄H₆₆N₁₂O₈ 
• 1356410-05-3 C₃₅H₅₅N₅O₇ 
• 1356410-04-2 C₃₅H₅₅N₅O₇ 
• 1356410-06-4 C₄₉H₆₉N₅O₈ 
• 1356410-08-6 C₅₂H₈₂N₁₂O₁₉S 
• 1356410-07-5 C₅₂H₈₂N₁₂O₁₉S 
• 1356410-10-0 C₆₂H₉₅N₁₅O₁₈ 
• 1356410-09-7 C₆₂H₉₅N₁₅O₁₈ 
• 1356409-07-8 C₁₄H₁₄O 
• 1356409-74-9 C₃₈H₅₇N₉O₈ 
• 1356409-73-8 C₃₈H₅₇N₉O₈ 
• 1356409-36-3 C₄₃H₆₁N₉O₁₀ 

Relevant articles and documents

Antibiotic Conjugates with an Artificial MECAM-Based Siderophore Are Potent Agents against Gram-Positive and Gram-Negative Bacterial Pathogens

The development of novel drugs against Gram-negative bacteria represents an urgent medical need. To overcome their outer cell membrane, we synthesized conjugates of antibiotics and artificial siderophores based on the MECAM core, which are imported by bacterial iron uptake systems. Structures, spin states, and iron binding properties were predicted in silico using density functional theory. The capability of MECAM to function as an effective artificial siderophore in Escherichia coli was proven in microbiological growth recovery and bioanalytical assays. Following a linker optimization focused on transport efficiency, five β-lactam and one daptomycin conjugates were prepared. The most potent conjugate 27 showed growth inhibition of Gram-positive and Gram-negative multidrug-resistant pathogens at nanomolar concentrations. The uptake pathway of MECAMs was deciphered by knockout mutants and highlighted the relevance of FepA, CirA, and Fiu. Resistance against 27 was mediated by a mutation in the gene encoding ExbB, which is involved in siderophore transport.

PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cance

Modification of N-terminal α-amino groups of peptides and proteins using ketenes

A method of highly selective N-terminal modification of proteins as well as peptides by an isolated ketene was developed. Modification of a library of unprotected peptides XSKFR (X varies over 20 natural amino acids) by an alkyne-functionalized ketene (1) at room temperature at pH 6.3 resulted in excellent N-terminal selectivity (modified α-amino group/modified ε-amino group = >99:1) for 13 out of the 20 peptides and moderate-to-high N-terminal selectivity (4:1 to 48:1) for 6 of the 7 remaining peptides. Using an alkyne-functionalized N-hydroxysuccinimide (NHS) ester (2) instead of 1, the modification of peptides XSKFR gave internal lysine-modified peptides for 5 out of the 20 peptides and moderate-to-low N-terminal selectivity (5:1 to 1:4) for 13 out of the 20 peptides. Proteins including insulin, lysozyme, RNaseA, and a therapeutic protein BCArg were selectively N-terminally modified at room temperature using ketene 1, in contrast to the formation of significant or major amounts of di-, tri-, or tetra-modified proteins in the modification by NHS ester 2. The 1-modified proteins were further functionalized by a dansyl azide compound through click chemistry without the need for prior treatment.